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Background/objectives: It has been reported that adverse fetal outcomes are more prevalent
in pregnant women with asthma than they are in women without asthma. In our study, we
investigated the effect that the severity of asthma during pregnancy has on the risk of a small
for gestational age (SGA) infant, low birth weight (LBW), and preterm birth.
Methods: A population-based cohort of 13,007 pregnancies from asthmatic women was recon-
structed through the linking of three of Quebec’s (Canada) administrative databases covering
the period between 1990 and 2002. A two-stage sampling cohort design was used to collect
additional information on the selected women’s life-style habits via a mailed questionnaire.
Asthma severity during pregnancy was measured with a validated database index. A logistic
regression model was used to obtain the adjusted odds ratios of SGA, LBW and preterm birth
as a function of the level of asthma severity.
Results: The proportions of women with mild, moderate and severe asthma were 82.5%, 12.5%
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Effect of maternal moderate to severe asthma 1279(nZ 1274) response rate. Final estimates showed that the risk of SGA was significantly higher
among severe (OR:1.48, 95%CI: 1.15e1.91) and moderate asthmatic women (OR: 1.30,
95%CI:1.10e1.55) than mild asthmatic women. No significant associations were found between
asthma severity, preterm birth and LBW.
Conclusions: Mothers with severe and moderate asthma during pregnancy have a higher risk of
SGA babies than those with mild asthma.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Asthma is one of the most frequent chronic diseases
encountered during pregnancy and its prevalence among
pregnant women is estimated to be between 4 and 7%.1e5
Lack of oxygen to the fetus can lead to perinatal
mortality, intrauterine growth retardation, preterm birth or
neonatal hypoxia.6,7 Maternal severe or uncontrolled
asthma is potentially dangerous to the fetus since it can
induce hypoxia combined with respiratory alkalosis that
decrease the placental blood flow.8,9 Decreased fetal blood
oxygen could result in both an abnormal growth and
abnormal fetal development.10e12 Indeed, adverse fetal
outcomes such as preterm birth and low birth weight have
been reported as being more prevalent in pregnant women
with asthma than women without asthma.13e17 However,
scientific evidence is scarce regarding the impact of asthma
severity during pregnancy on these perinatal outcomes.
Jana et al. found that the mean birth weight of neonates
born to mothers who were hospitalized for asthma during
pregnancy was about 400 g (p< 0.05) lower than that of
neonates born to asthmatic mothers who were not hospi-
talized.18 These results have also been confirmed in other
studies.19,20 Moreover, Fitzsimmons reported a statistically
significant increased incidence of small for gestational age
(SGA) babies born to mothers who were hospitalized for
asthma during pregnancy compared to asthmatic mothers
who were not hospitalized.19
Although studies have reported associations between
severe exacerbations requiring hospitalization during
pregnancy and adverse perinatal outcomes, there is little
evidence on the impact of the level of asthma severity on
perinatal outcomes. Only a few small studies investigated
the association between the level of asthma severity during
pregnancy and perinatal outcomes and yielded inconsistent
results. Bracken et al. found that intrauterine growth
retardation (IUGR, defined as below the tenth percentile of
birth weight for gestational age) was more common among
infants of mothers with mild persistent to moderate
persistent asthma as compared to those with no symptoms
or medication use.21 However, in a more recent study,
Dombrowski et al. found that the rate of pre-term birth (37
weeks or less) and SGA did not vary according to the level
asthma severity.22 Moreover, Stenius-Aarniala et al. found
no significant difference in birth weight between mothers
with moderate to severe asthma and mothers with very
mild to mild asthma.23 But the large study from Enriquez R
et al. reported lower birth weight among infants of women
with exacerbated asthma during pregnancy.24
Methodological differences between studies, such as the
definition of asthma severity, the choice of the outcome,and lack of adjustment for potential confounding variables,
as well as the small sample size make it difficult to
conclude with a reasonable degree of certainty that preg-
nant women with severe asthma are more likely to give
birth to infants with adverse perinatal outcomes than
women with mild asthma.
A population-based cohort of 13,007 pregnancies of
asthmatic women was reconstructed from the Canadian
province of Quebec to further investigate the effect of the
severity of asthma during pregnancy on the risk of an SGA
infant, low birth weight (LBW), and preterm birth.Materials and methods
Source of data
The data for our study came from three administrative
databases of the province of Quebec; the Re´gie de l’As-
surance Maladie du Quebec (RAMQ), MED-ECHO, and the
Fichier des e´ve´nements de´mographiques du Que´bec (birth
and death registries) managed by the Institut de la statis-
tique du Que´bec (ISQ)). The RAMQ databases provide
information on the medical services dispensed to all resi-
dents of Quebec since the entire population is covered by
the RAMQ medical insurance and on prescribed medications
filled in community pharmacies by residents covered by the
RAMQ’s Public Drug Insurance Plan. Between 1980 and
1997, most notably the elderly and social assistance bene-
ficiaries were covered with the Public Drug Insurance Plan.
However, since the enactment of mandatory drug coverage
in 1997, the RAMQ’s Public Drug Insurance Plan provides
coverage for an additional 1.7 million adherents, mainly
workers and their families who have no access to a private
drug insurance plan from their workplace.25 Approximately
43% of the population of Quebec is covered by the RAMQ
Public Drug Insurance Plan. The RAMQ Prescription Medi-
cations database provides information on dispensed medi-
cations e i.e. date of filling, name, dose, quantity, dosage
form and duration of the prescription e while the RAMQ
Medical Services database provides information on medical
services dispensed in a clinic, an emergency department
(ED) or a hospital and includes information pertaining to
date, diagnosis coded with ICD-9, where the service was
dispensed, etc. Data recorded in the RAMQ Prescription
Medications database and asthma diagnoses recorded in the
RAMQ Medical Services database have been formally eval-
uated and found to be valid.26,27 The MED-ECHO database is
a provincial database which records data on acute care
hospitalizations and covers all residents of Quebec.27 The
Fichier des e´ve´nements de´mographiques provides
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Quebec. The data obtained from three administrative
databases were later supplemented by data retrieved from
the mailed questionnaires filled by a number of selected
mothers. The additional information which are not included
in the administrative databases and that were gathered by
the questionnaire are mostly about siblings and maternal
life styles during pregnancy.
Study design and population
A two-stage sampling cohort design (balanced selection)
was used for this study.28e31 In the ‘‘balanced design’’ at
the second stage of sampling, individuals should be
selected according to their exposure/disease characteris-
tics to have an equal number of individuals in each cell of
the second stage cross table.28,30 This strategy decreases
the occurrence of small cells (responsible for large vari-
ance) by forcing an overrepresentation of individuals who
belong to small groups in the exposure/disease cross-clas-
sification.28 In our study, the first stage of sampling corre-
sponds to the cohort formed of singleton pregnancies of
asthmatic women ending in a delivery (live birth or still-
birth) between January 1, 1990 and December 31, 2002 in
the province of Quebec (Canada). Pregnant women and
newborns were identified in the RAMQ databases using
diagnostic and act codes related to prenatal care, preg-
nancy complications, and deliveries.32 Moreover, to be
included in our cohort, a women must have been between
13e50 years of age at the beginning of their pregnancy,
have had a diagnosis of asthma (9th international classifi-
cation of diseases (ICD-9) code 493, except 493.2), one or
more prescriptions for an asthma medication dispensed in
the two years prior or during pregnancy, and being covered
by the RAMQ Drug Insurance Plan for at least one year prior
to, and throughout the duration of pregnancy. We allowed
a maximum of four pregnancies per woman to enter in the
cohort and only the more recent ones were kept. For each
pregnancy, the data from RAMQ and MED-ECHO databases
were obtained one year before and during pregnancy. The
date of the last menstruation was calculated using the
gestational age and date of birth of the infant obtained
from the MED-ECHO and RAMQ databases. This mother-child
cohort was then linked with the Fichier des e´ve´nements
de´mographiques database to obtain information on socio-
demographic variables for the mothers and the newborns.
At the second stage of sampling, we selected a sample of
women to whom a questionnaire was sent by mail, using
a balance sampling strategy.28,30 This strategy oversamples
women with moderate to severe asthma who had a SGA
baby, a LBW baby, or a preterm delivery in order to increase
the statistical power.28 A maximum of two pregnancies per
woman were selected at this stage of sampling. Selected
women had to be at least 18 years old to be eligible for the
second stage. For all pregnancies selected at this stage,
the RAMQ provided us with the current postal addresses of
the mother and their spoken language.
The questionnaire was used to obtain information on life
styles, maternal characteristics, and pregnancy related
variables that are not recorded in the administrative
databases. The questionnaire was pre-tested for clarity andassessed the ability of the women to remember the answers
to the questions that related to a pregnancy that occurred
several years ago. First, we sent 3168 questionnaires to
selected women. A second questionnaire was sent a month
and half later as a reminder to women who did not respond
to the first mailing. A 10$ compensation was given to
women who completed the questionnaire. The question-
naires’ data were recorded in a computerized database,
using a double entry method to improve data quality.
Linkage between data obtained from the RAMQ and MED-
ECHO databases, ISQ, and the filled questionnaires as well
as the request of the names and the mailing address of
selected women at the second stage of sampling was
approved by the Commission d’acce`s a` l’information du
Quebec (CAI). This research project was also approved by
the ethic committee of the Hoˆpital du Sacre´-Cœur de
Montre´al (Montreal, Quebec, Canada).
Exposure
The main exposure variable is the level of severity of
maternal asthma during pregnancy measured with an index
that we had previously developed and validated.33 This
severity index is based upon the criteria detailed in the
Canadian Asthma Consensus Guidelines for the assessment
of the severity of asthmatic patients, who are already
taking anti-asthmatic medications.34 Three levels of
asthma severity were defined over a 12-month period based
upon the following: the average daily dose of inhaled
corticosteroid (ICS) in beclomethasone-chloroflurocarbon
(CFC) equivalent, the use of additional controller thera-
pies defined as at least 6 filled prescriptions of inhaled long-
acting beta2-agonists, theophylline, or leukotriene-
receptor antagonists within a 12-month period, the
average number of doses of SABA per week, and the pres-
ence of markers of moderate to severe asthma exacerba-
tions e a filled prescription of oral corticosteroids, an
emergency department (ED) visit for asthma, or a hospital-
ization for asthma.35 Details of the severity index are
provided in the electronic attachment.
Outcomes
The outcomes of interest included SGA newborns, preterm
birth and LBW. SGA was defined as a birth weight below the
10th percentile for gestational age and gender, using new
Canadian standards.36,37 Preterm birth was defined as
a birth before 37 weeks of gestation while LBW was defined
as birth weight lower than 2500 g. Validated algorithms
based on data recorded in the RAMQ, MED-ECHO or ISQ
databases were used to measure these variables.38
Potential confounding variables
Four categories of variables were considered as potential
confounding variables. Maternal characteristics which
include age at beginning of pregnancy (<18, 18e34, >34
years),39 receiving social assistance benefits in the year
before or during pregnancy (yes/no), urban residency at
delivery (yes/no), being primiparous (yes/no), maternal
education (highest level reached) (elementary school, high
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pregnancy (<$18000, $18000e$46000, >$46000)39 and birth
weight (<2.5, 2.5e5, >5 kg). Pregnancy-related variables
which include high risk pregnancies (yes/no), gestational
diabetes (yes/no), pregnancy-induced hypertension (yes/
no), gynecologist or obstetrician visit during pregnancy
(yes/no), number of prenatal visits (5, 6e14, >14),
maternal weight gain during pregnancy (<8, 8e16, >16 kg),
maternal body mass index (BMI) (<18.5, 18.5e24.9, 24.9e
29.9, >29.9) at beginning of pregnancy and another
preterm or LBW infant prior to the current delivery (yes/
no).40 Maternal co-morbidities which include diabetes
mellitus (yes/no), and chronic hypertension (yes/no). Life
styles which include maternal & paternal cigarette smoking
during pregnancy (yes/no) and maternal alcohol consump-
tion during pregnancy (yes/no).
Data analysis
Descriptive statistics were used to report the characteris-
tics of the pregnancies included in the first stage of
sampling (cohort) and those selected at the second stage of
sampling as a function of asthma severity levels during
pregnancy. We also calculated the prevalence of perinatal
outcomes by maternal asthma severity level among all
pregnancies included in the cohort.
Crude and adjusted odds ratios (OR) for SGA, LBW and
preterm birth comparing pregnancies of mild asthmatic
women with those with moderate and severe forms of the
disease were first estimated for the first stage of sampling
using separate Generalized Estimation Equation (GEE)
models. The GEE models can estimate the effect of inde-
pendent variables, including the main exposure and con-
founding variables, on several types of outcomes, namely
dichotomous outcomes such as the presence or the absence
of SGA, LBW or preterm delivery with a logit function as
well as take into account the fact that a woman could
contribute more than one pregnancy to the analysis by
estimating the correlation between consecutive
pregnancies.
We also obtained adjusted OR estimates based on
pregnancies selected at the second stage of sampling and
GEE models that adjusted for confounding variables
collected at the first (administrative databases) and second
(questionnaire) stages of sampling. The best reduced
models were found using a backward selection strategy,
keeping in the model only covariates that were found to act
as a confounder or those that were significantly associated
with the outcome (p-value< 0.05).
The final adjusted OR estimates were then obtained by
correcting the second stage adjusted estimates with the
second stage sampling fractions and estimates formed at
the first stage of sampling using the methodology proposed
by Collet et al.28
Results
At the first stage of sampling, the cohort included 13,007
singleton pregnancies of 9925 asthmatic women. Among
them, 7425 women contributed to the analysis with only
one pregnancy, and 2500 with at least two pregnancies.From this cohort, a total of 3347 pregnancies were selected
for the second stage of sampling. The RAMQ provided us
with the addresses of 3152 women which corresponded to
3168 pregnancies. We received 1274 completed question-
naires which represents a response rate of 40.2%.
Table 1 shows the distribution of the variables retrieved
from the administrative databases by asthma severity level
for women included in the first stage of sampling. In our
cohort, 82.6%, 12.4% and 5.0% of pregnancies were from
women with mild, moderate and severe asthma, respec-
tively. A high risk pregnancy was more frequent among
pregnancies of severe asthmatic than moderate and mild
ones (40.5% vs. 36.2% and 35.9%, respectively).
In Table 2, we present the distribution of variables
retrieved from the questionnaire by asthma severity level
among pregnancies selected at the second stage of
sampling. The prevalence of maternal cigarette smoking
during pregnancy was higher among women with severe
asthma (67.1%) compared to women with moderate and
mild asthma (57.7% and 63.9%), respectively. Also, on
average women with severe asthma had a lower annual
family income and were less likely to have post high school
education. Maternal weight gain during pregnancy was
more important among women with severe asthma (58.5%
>16 kg) than in women with moderate or mild asthma
(40.7% and 39.1%, respectively). Also, these women had
a higher pre-pregnancy BMI as compared to women in the
two other groups.
We compared the characteristics of 1274 pregnancies of
women who answered to the questionnaires with the
characteristics of the 1894 pregnancies of women who did
not answer. Overall, there was no difference between the
responders and non responders except for social assistance
(77.2 % vs 84.1%), urban residency (77.2% vs 83.7%), being
primiparous (59.2 vs. 66.9%), and the number of prenatal
visits (14.3 vs. 20.6% for 5). The details of this analysis are
available in the electronic attachment.
We identified 1886 SGA babies (14.5%) from the first
stage of sampling (Table 3). The prevalence of SGA babies
was higher among pregnancies of severe than moderate or
mild asthmatic women: 19.5%, 17.4% and 13.8%, respec-
tively. However, the same trend was not observed for the
two other outcomes. The prevalence of LBW and preterm
birth was about 10% for all three categories of asthma
severity. The prevalence of SGA, LBW and preterm birth
found among asthmatic women in our study was higher than
provincial statistics (Que´bec, Canada) that showed a prev-
alence of 8.3%, 4.3% and 6.3% for these perinatal
outcomes.41 The prevalence of adverse perinatal outcomes
was much higher at the second stage of sampling since SGA,
LBW and premature infants were oversampled.
We present the main findings of this study in Table 4 that
are the first stage and final estimates of the ORs for the
three perinatal outcomes comparing levels of asthma
severity during pregnancy. Final estimates showed that the
risk of SGA was significantly higher among severe (OR: 1.48,
95%CI: 1.15e1.91) and moderate asthmatic women (OR:
1.30, 95%CI:1.10e1.55) than mild asthmatic women. On the
other hand, final estimates showed a 25% non significant
increased risk of LBW (ORZ 1.25; 95% CI: 0.87e1.80) and
no increased risk of preterm birth 0.93 (0.67e1.29) among
severe as compared to mild asthmatic mothers. Similar
Table 1 Characteristics of all study women included in the cohort by asthma severity level during pregnancy (database driven
variables, nZ 13,007).
Pregnancies of
Severe asthmatic
women NZ 652 (5.0%)
Pregnancies of
moderate asthmatic
women NZ 1618 (12.4)
Pregnancies of mild
asthmatic women
NZ 10,737 (82.6)
P-value
Numbers (%)
Maternal characteristics
Age at beginning of pregnancy
<18 years old 39 (6.0) 89 (5.5) 747 (7.0)
18e34 years old 552 (84.7) 1401 (86.6) 9380 (87.4)
>34 years old 61 (9.4) 128 (7.9) 610 (5.7) <0.0001
Recipient of social assistancea 541 (83.0) 1312 (81.1) 8493 (79.1) 0.0151
Urban residency at delivery 532 (81.6) 1287 (79.5) 8709 (81.1) 0.2591
Primiparous 391 (60.3) 1067 (66.2) 7319 (68.4) <0.0001
Pregnancy related variables
High risk pregnancy 264 (40.5) 585 (36.2) 3851 (35.9) 0.0580
Gestational diabetes 64 (9.8) 132 (8.2) 804 (7.5) 0.0718
Pregnancy induced hypertension 55 (8.4) 115 (7.1) 676 (6.3) 0.0569
Gynecologist or obstetrician
visit during pregnancy
554 (85.0) 1349 (83.4) 8810 (82.1) 0.0863
Number of prenatal visits
5 95 (14.6) 253 (15.6) 1700 (15.8)
6e14 481 (73.8) 1173 (72.5) 7823 (72.9)
>14 76 (11.7) 192 (11.9) 1214 (11.3) 0.8833
Asthma related variables measured during pregnancy
ICS use (mg per day)b
0 57 (8.7) 404 (25.0) 7268 (67.7)
0e500 364 (55.8) 979 (60.5) 3469 (32.3)
500e1000 106 (16.3) 228 (14.1) 0 (0.0)
>1000 125 (19.2) 7 (0.4) 0 (0.0) <0.0001
SABA use (number of doses per week)c
0 0 (0.0) 12 (0.7) 4961 (46.2)
>0e3 0 (0.0) 22 (1.4) 4177 (38.9)
>3 652 (100.0) 1584 (97.9) 1599 (14.9) <0.0001
Leukoteriene-receptor
antagonists use
14 (2.2) 14 (0.9) 6 (0.1) <0.0001
Oral corticosteroids use 384 (58.9) 260 (16.1) 336 (3.1) <0.0001
1 respiratory physician visit 170 (26.1) 179 (11.1) 401 (3.7) <0.0001
1 ED visit for asthma 457 (70.1) 444 (27.4) 710 (6.6) <0.0001
1 hospitalization for asthma 90 (13.8) 49 (3.0) 57 (0.5) <0.0001
Maternal co-morbidities
Chronic diabetes 14 (2.2) 56 (3.5) 244 (2.3) 0.0133
Chronic hypertension 23 (3.5) 43 (2.7) 238 (2.2) 0.0652
a Social assistance status in the year before pregnancy.
b ICS daily dose in beclomethasone-CFC equivalent over a 12-month period.
c SABA: short-acting inhaled beta2-agonist.
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with moderate and mild asthma were compared.Discussion
Our results show that severe and moderate asthma during
pregnancy were significantly associated with a 48% and 30%
increased risk of SGA babies, respectively, when compared
to mild asthma. On the other hand, we found a nonsignificant increased risk of LBW babies and no increased
risk of preterm delivery among severe and moderate asth-
matic women. Post-hoc power calculations revealed that, if
present, we had more than 80% power to detect an
increased risk of LBW and preterm birth of 40% among
severe asthmatic women and of 25% among moderate
asthmatic women when compared to mild asthmatic
women.
Some physiologic hypotheses can explain our results.
The effects of chronic oxygen deprivation on the fetus are
Table 2 Characteristics of women selected at the second stage of sampling by asthma severity level during pregnancy
(questionnaire driven variables, nZ 1274).
Pregnancies of
Severe asthmatic
women NZ 82 (6.4%)
Pregnancies of
moderate asthmatic
women NZ 189 (14.8%)
Pregnancies of
mild asthmatic
women NZ 1003 (78.7%)
p-value
Numbers (%)
Maternal characteristics
Maternal education (highest level attained)
Elementary school 12 (14.6) 7 (3.7) 86 (8.6)
High school 59 (72.0) 143 (75.7) 746 (74.4)
College & University 10 (12.2) 35 (18.5) 149 (14.9)
Unknown 1 (1.2) 4 (2.1) 22 (2.2) 0.0798
Annual family income during pregnancy
<$ 18,000 56 (68.3) 115 (60.9) 591 (58.9)
$18,001e$46,000 22 (26.8) 52 (27.5) 333 (33.2)
>$46,001 2 (2.4) 35 (9.5) 56 (5.6)
Unknown 2 (2.4) 4 (2.1) 23 (2.3) 0.1471
Maternal weight at birth
<2.5 kg 16 (19.5) 27 (14.3) 205 (20.4)
2.5e5.0 kg 58 (70.7) 141 (74.6) 680 (67.8)
>5.0 kg 1 (1.2) 4 (2.1) 11 (1.1)
Unknown 7 (8.5) 17 (9.0) 107 (10.7)
Pregnancy related variables 0.4100
Maternal weight gain during pregnancy
<8 kg 9 (11.0) 24 (12.7) 146 (14.6)
8e16 kg 19 (23.2) 77 (40.7) 435 (43.4)
>16 kg 48 (58.5) 77 (40.7) 392 (39.1)
Unknown 6 (7.3) 11 (5.8) 30 (3.0) 0.0012
Maternal BMI pre-pregnancy
<18.5 12 (14.6) 17 (9.0) 149 (14.9)
18.5e24.9 41 (50.0) 99 (52.4) 527 (52.5) 0.3589
24.9e29.9 14 (17.1) 40 (21.2) 177 (17.7)
>29.9 14 (17.1) 26 (13.8) 115 (11.5)
Unknown 1 (1.2) 7 (3.7) 35 (3.5)
Preterm birth prior to
the current delivery
11 (13.4) 22 (11.6) 177 (17.7) 0.2370
Unknown 0 (0.0) 2 (1.1) 7 (0.7)
LBW infant prior to the
current delivery
6 (7.3) 23 (12.2) 163 (16.3) 0.0673
Unknown 0 (0.0) 0 (0.0) 9 (0.9)
Life style habits
Maternal cigarette smoking during pregnancy
Yes 55 (67.1) 109 (57.7) 641 (63.9) 0.4521
No 27 (32.9) 79 (41.8) 356 (35.5)
Unknown 0 (0.0) 1 (0.5) 6 (0.6)
Paternal cigarette smoking
during pregnancy
Yes 40 (48.8) 95 (50.3) 513 (51.2) 0.4689
No 39 (47.6) 93 (49.2) 469 (46.7)
Unknown 3 (3.7) 1 (0.5) 21 (2.1)
Maternal alcohol consumption during pregnancy
Yes 17 (20.7) 34 (18.0) 170 (17.0)
No 64 (78.1) 149 (78.8) 795 (79.2) 0.7015
Unknown 1 (1.2) 6 (3.2) 38 (3.8)
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Table 3 Prevalence of adverse perinatal outcomes by asthma severity level: first and second stages of sampling.
Pregnancies of Severe
asthmatic women
Pregnancies of moderate
asthmatic women
Pregnancies of mild
asthmatic women
Number (%)
1st stage (NZ 13,007) Number of patients 652 1618 10737
SGA 127 (19.5) 281 (17.4) 1478 (13.8)
LBW 65 (10.0) 160 (9.9) 972 (9.1)
Preterm 65 (10.0) 146 (9.0) 1129 (10.5)
2nd stage (NZ 1274)a Number of patients 82 189 1003
SGA 26 (31.7) 48 (25.4) 416 (41.5)
LBW 13 (15.9) 18 (9.5) 231 (23.0)
Preterm 12 (14.6) 15 (7.9) 268 (26.7)
a The prevalence of outcomes obtained at the second stage of sampling is not representative of the real prevalence because of the
sampling method which oversamples pregnancies with an adverse perinatal outcome that we used to select women at this stage of
sampling.
1284 F. Firoozi et al.described by several clinicians and were also confirmed by
observation of pregnancies at high altitude and in females
with congenital heart diseases.12 Maternal asthma can
induce hypoxia combined with respiratory alkalosis that
decreases the placental blood flow.8,9 Lack of oxygen to the
fetus and the long-term effect of hypoxemia could affect
fetal growth.10e12 Our results support the findings of Schatz
et al. who reported a significant association between lower
maternal mean FEV1 during pregnancy and the risk of
a birth weight in the lower quartile of the infant population
(pZ 0.002) and ponderal indices< 2.2 (suggestive of
asymmetric intrauterine growth retardation) (p< 0.05), butTable 4 Crude and adjusted odds ratios for perinatal outcomes
women.
OR (95% CI)
SGA
1st stage Crude
Adjusted
Final estimatesa Adjusted
LBW
1st stage Crude
Adjusted
Final estimatesa Adjusted
Preterm birth
1st stage Crude
Adjusted
Final estimatesa Adjusted
a Final estimates obtained by adjusting the second stage estimates
b Adjusted for recipient of social assistance in the year before preg
c Adjusted for primiparous, chronic diabetes, maternal cigarette smo
gain during pregnancy, preterm birth prior to the current delivery, an
d Adjusted for recipient of social assistance in the year before pre
nancy, gynaecologist or obstetrician visit during pregnancy, number o
e Adjusted for recipient of social assistance in the year before pregn
chronic hypertension, maternal weight at birth, maternal weight gain
f Adjusted for recipient of social assistance in the year before pregna
pregnancy, number of prenatal visits, and chronic diabetes and hype
g Adjusted for high risk pregnancy, gynaecologist or obstetrician vi
gain during pregnancy and preterm birth prior to the current deliveryno increased risk of preterm birth and LBW infants.7 These
results suggest that severe maternal asthma is more likely
to affect the growth of the baby than the timing of the
delivery which is more precisely captured by the SGA
measure than the weight at birth alone.
The literature reports conflicting results on the associ-
ation between the severity of maternal asthma and peri-
natal outcomes. The results found in this study are
consistent with those of Fitzsimmons et al. and Mabie et al.
19,42 who reported a significant increased risk of SGA babies
associated with severe asthma (pZ 0.02 and p< 0.05,
respectively). However, their definition of severe asthmacomparing severe and moderate asthmatic to mild asthmatic
Severe vs. Mild Moderate vs. Mild
1.52 (1.24e1.85) 1.32 (1.14e1.51)
1.44 (1.18e1.76)b 1.30 (1.13e1.49)b
1.48 (1.15e1.91)c 1.30 (1.10e1.55)c
1.11 (0.85e1.45) 1.10 (0.92e1.31)
1.04 (0.80e1.37)d 1.08 (0.90e1.29)d
1.25 (0.87e1.80)e 1.04 (0.81e1.34)e
0.94 (0.72e1.23) 0.84 (0.70e1.01)
0.90 (0.69e1.18)f 0.82 (0.68e0.99)f
0.93 (0.67e1.29)g 0.83 (0.65e1.05)g
with the second stage sampling fractions.
nancy, primiparous and high risk pregnancy.
king during pregnancy, maternal weight at birth, maternal weight
d LBW infant prior to the current delivery.
gnancy, urban residency at delivery, primiparous, high risk preg-
f prenatal visits and chronic hypertension.
ancy, primiparous, high risk pregnancy, number of prenatal visits,
during pregnancy, and LBW infant prior to the current delivery.
ncy, high risk pregnancy, gynaecologist or obstetrician visit during
rtension.
sit during pregnancy, number of prenatal visits, maternal weight
.
Effect of maternal moderate to severe asthma 1285was quite restrictive including only patients who were
hospitalized for status asthmaticus, had mechanical venti-
lation or required chronic maintenance therapy with oral
prednisone. Another factor that differentiates these
studies from our study is the lack of any adjustment for
confounding variables.19,42 On the other hand, our results
differ from those of Perlow et al., Greenberg et al. and
Dombrowski et al. who found no significant increased risk of
SGA associated with severe asthma.22,43,44
Bracken et al. used a definition of asthma severity that is
closer to ours (based on asthma symptoms and medication
use), but reported inconsistent results. Indeed, they repor-
ted adjusted significant increased risks of IUGR (defined as
below the tenth percentile of birth weight for gestational
age) that ranged from 1.74 to 1.98 among women with
moderate to mild persistent asthma and no significant
increased risk among women with severe persistent asthma
(ORZ 1.39; 95% CI: 0.69e2.77) as compared to asthmatic
women with no symptoms or medication use.21
There are several studies that have evaluated the asso-
ciation between severe asthma and the risk of preterm
delivery.7,18,19,21,23,42e44 Perlow et al. found a significant
increased risk of preterm delivery among infants of corti-
costeroid dependent mothers as compared to none-
corticosteroid dependant mothers. However, it is difficult
to know if this increased risk is the result of severe asthma
or the corticosteroid therapy itself.44 Jana et al. and
Bracken et al. have found a non significant increased risk of
preterm birth when they compared severe asthmatic
mothers to mild ones (1.61 and 1.67 respectively), but the
small sample size of these studies and the lack of adjust-
ment for confounding variables in the Jana et al. study
make it difficult to come to any conclusion.18,21 Several
other studies also evaluated the effect of maternal asthma
severity on preterm birth and reported no
association.7,19,23,42,43
A significant increase in LBW (OR:5.1, 95%CI: 1.6e17.0)
was found by Perlow et al. among infants of corticosteroid
dependent mothers as compared to non-corticosteroids
dependent mothers.44 Also, Jana et al. found a signifi-
cantly higher incidence of LBW among infants of 15 mothers
requiring as compared to 167 mothers not requiring emer-
gency admission (53.3% vs. 20.5%; p< 0.01).18 Greenberg
et al. and Fitzsimmons et al. have found a significant
decrease in mean birth weight (ranging from 300 to 500 g)
among women who were hospitalized for asthma during
pregnancy.19,43 However, the lack of adjustment for any
confounding variables including maternal smoking and also
the use of a much stricter definition of severe asthma could
explain the discrepancies between these studies and our
study. In concordance with our results, Stenius-Aarniala
et al. found no difference between the birth weight of
infants of mothers with moderate to severe and very mild
to mild asthma (3418 vs. 3479 g).23
The high prevalence of cigarette smoking during preg-
nancy among women with severe asthma could be
explained by their low socio-economic status and also the
fact that we oversampled the women with moderate to
severe asthma who had a SGA baby, a LBW baby, or
a preterm delivery.
Our study has some limitations that should be taken into
account when interpreting the results. Firstly, askingquestions related to a pregnancy that occurred many years
ago could result in recall bias. However, a recent study has
demonstrated that ‘‘maternal reports of perinatal events in
which they directly participated can be accurately and
reliably reported 10 to 15 years after birth.’’.45 Secondly,
the response rate of the mailed questionnaire was about
40%, and the risk of participation bias could have been
present, if women who answered the questionnaire were
different from women who did not answer. In our study,
however, it is reassuring to observe that responders were
quite similar to non-responders for all first-stage potential
confounding variables (data available upon request).
Thirdly, we cannot fully differentiate the effect of asthma
medication use from asthma severity itself and it is possible
that some of the observed adverse perinatal outcomes were
due to the use of asthma medications. Finally, our cohort is
less representative of women in the higher socio-economic
level. This could explain, at least in part, the high preva-
lence of cigarette smoking among women with severe
asthma. High prevalence of cigarette smoking can also be
explained by the oversampling of women with moderate to
severe asthma who had a SGA baby, a LBW baby, or
a preterm delivery at the second-stage of sampling. The
non representativeness of our cohort in this study would be
a threat to external validity only if socio-economic status is
an effect modifier for the associations under study i.e.
severity of asthma and perinatal outcomes. But there is no
evidence in the literature suggesting that the impact of
severity of asthma on newborns differs according to the
socio-economic status of the mother. However, this possi-
bility cannot be ruled out completely.
Our study has also several strengths. Firstly, we had
a very large sample size, which provided adequate power to
detect small but clinically important differences. Secondly,
the measurement of the severity of asthma during preg-
nancy was based on a validated database index, which
assesses asthma severity among patients already under
treatment.34 Thirdly, the gestational age at birth and birth
weight were validated by comparing the database values to
medical chart values and were found to be highly valid.38
Fourthly, we used an SGA definition which is based on
new Canadian standards and considers the Canadian growth
pattern in its definition.36,37 Finally, the two-stage sampling
design allowed us to obtain confounding variables that are
not recorded in the administrative databases; for example,
cigarette smoking and environmental exposure during
pregnancy. Having the possibility to adjust the association
under study for a large number of potential confounding
variables led to a better model, more representative of
‘‘real life,’’ one that takes into consideration the wide
variety of variables that may intervene in the development
of the foetus.
In conclusion, the results of this study provide evidence
that moderate and severe asthma could result in a higher
risk of SGA babies than mild asthma with no detectable
impact on LBW and prematurity.Conflict of interest statement
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submitted manuscript.
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